Form 4: Phathom CEO Basta Reports Stock Vesting, Tax Sale

Phathom Pharmaceuticals CEO Steven L. Basta reported the vesting of performance stock units and a subsequent sale of shares to cover tax obligations.

Summary

• Steven L. Basta, President and CEO of Phathom Pharmaceuticals, Inc., reported transactions involving the company's common stock.
• On February 10, 2026, Basta acquired 12,362 shares of common stock upon the vesting of performance stock units (PSUs) granted on April 3, 2025, based on the achievement of performance criteria.
• Concurrently, Basta disposed of 6,277 shares of common stock at a price of $12.82 per share on February 10, 2026, to satisfy tax withholding obligations related to the PSU vesting.
• Following these reported transactions, Basta's direct beneficial ownership stands at 373,315 shares.
• The reported beneficial ownership prior to the disposition included 2,410 shares acquired under the Phathom Pharmaceuticals, Inc. employee stock purchase plan in January 2026.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a moderately positive event, reflecting the achievement of performance milestones and routine executive compensation, with no immediate negative implications beyond standard tax-related share sales.

Positives

• The vesting of 12,362 performance stock units indicates the achievement of specific performance criteria, suggesting positive operational or strategic milestones for Phathom Pharmaceuticals.
• The acquisition of 2,410 shares through the employee stock purchase plan in January 2026 demonstrates continued insider investment and confidence in the company by the CEO.

Negatives

• The disposition of 6,277 shares, while for tax withholding purposes, results in a reduction of the CEO's direct beneficial ownership.

Future Outlook

NA

Industry Context

StockSavvy.ai notes that Form 4 filings are routine disclosures of insider transactions, providing transparency into executive stock ownership changes. The vesting of performance-based awards is a common compensation practice in the pharmaceutical industry, aligning executive incentives with company performance.

Stakeholder Impact

• Shareholders: Provides transparency into executive compensation and alignment of interests through equity ownership.
• Employees: The employee stock purchase plan participation indicates a broader employee investment opportunity.

Key Dates

Recommendation

The filing details routine insider transactions related to executive compensation, specifically the vesting of performance stock units and a subsequent sale for tax purposes. While the vesting indicates performance achievement, the overall impact on the company's fundamentals or strategic direction is neutral. There is no new information to warrant a change in investment thesis, thus a 'hold' recommendation is appropriate.

Keywords

Phathom Pharmaceuticals, PHAT, Steven L. Basta, Form 4, Insider Trading, Stock Vesting, Performance Stock Units, Tax Withholding, CEO, Director, Equity Compensation